Drug intelligence / Profile preview

FLASH-001

Development stage: Unknown
Lead developer: Flashpoint Therapeutics
Modality: Nanoparticles → Drug Delivery Systems, Small Molecules

Overview

FLASH-001 is a structural nanomedicine incorporating toll-like receptor 9 agonists, developed by Flashpoint Therapeutics for immuno-oncology applications. It represents a new molecular entity designed to stimulate the immune system via activation of toll-like receptor 9 (TLR9), which plays a role in innate immunity and can promote anti-tumor immune responses. The drug is being investigated primarily as an antineoplastic agent, with its lead indication being Merkel cell carcinoma. As of February 2025, it has reached Phase I/II clinical development for this cancer type[1][4].

Other names: FLASH 001FLASH001FLASH-001

Targets

TLR9 (Toll-like receptor 9)

Beyond the preview

Go deeper on FLASH-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FLASH-001.

Explore the full profile